Innovative GLP-1 Oral Medication Promises Significant Weight Loss

A groundbreaking development in weight management has emerged with Eli Lilly's new oral GLP-1 receptor agonist, orforglipron. In a recent late-stage clinical trial, participants with overweight, obesity, and type 2 diabetes experienced remarkable weight loss and improved blood sugar levels after using this once-daily pill.

Participants who received the highest dose of 36 milligrams lost an average of nearly 23 pounds (about 10.5% of their body weight) over a 72-week period. Additionally, the medication reduced their A1C levels—a key marker of blood sugar control—by approximately 1.8%. These results are promising, suggesting the pill's potential to effectively treat obesity and related metabolic conditions.

Compared to existing oral GLP-1 options such as Rybelsus, orforglipron offers the advantage of not requiring strict fasting or water restrictions, making it a more convenient option for many. Its development aims to provide an alternative to injectable treatments, which can be challenging for some patients.

The reported side effects were generally mild to moderate, with gastrointestinal discomfort, such as upset stomach, being the most common. If regulatory approval is granted, orforglipron could become an accessible and user-friendly treatment for millions struggling with obesity and type 2 diabetes.

Eli Lilly is also exploring additional uses for the medication, including potential benefits for high blood pressure and sleep apnea. With production already underway to meet anticipated demand, the company's chief scientific officer, Dr. Dan Skovronsky, highlighted the readiness to distribute the medication widely.

The trial findings, although not yet peer-reviewed, mark a significant step forward in oral obesity treatments and metabolic health management.

Source: https://medicalxpress.com/news/2025-08-glp-pill-people-pounds.html